CureVac Advances mRNA Precision Immunotherapy Pipeline for Solid Tumors and Glioblastoma
TÜBINGEN, Germany/BOSTON, USA – April 12, 2025 – CureVac N.V. (Nasdaq: CVAC), a global biotech company pioneering mRNA-based transformative medicines, today announced its financial results for the fourth quarter and full-year 2024, alongside a significant business update highlighting advancements in its oncology pipeline. The company is strategically developing both off-the-shelf and fully personalized precision immunotherapies targeting various solid tumor types.
A key highlight is the progress of CureVac’s new off-the-shelf program for squamous non-small cell lung cancer (sqNSCLC). Following recent IND and CTA submissions, the FDA has cleared the way for a Phase 1 study of their investigational precision immunotherapy, CVHNLC. Dosing of the first patient is anticipated in the second half of 2025. CVHNLC is a multiepitope mRNA immunotherapy comprising two constructs encoding eight tumor-associated antigens prevalent in sqNSCLC, including both established and novel antigens identified through their myNEO Therapeutics collaboration. This novel combination will be tested in conjunction with pembrolizumab.
Furthermore, Part B of CureVac’s Phase 1 study with the shared antigen precision immunotherapy candidate CVGBM in patients with resected glioblastoma has completed enrollment. Data from this part of the study, which involves CVGBM monotherapy at the 100 µg dose, and a decision on moving to Phase 2 are expected in the second half of 2025. Preliminary data from Part A of the CVGBM study presented in 2024 demonstrated promising cancer antigen-specific T-cell responses and a generally well-tolerated safety profile.
Dr. Myriam Mendila, Chief Scientific Officer at CureVac, emphasized the company’s approach: “Our approach to precision immunotherapy aims to induce a potent immune response that translates into clinical benefit for patients by applying the ability of mRNA to precisely and safely guide the immune system to one or more tumor antigens. With this approach, we aim to target earlier stages of cancer where there is a higher chance to increase cure rates.”
CureVac also anticipates selecting a second clinical candidate in its off-the-shelf oncology program in 2026, and its fully personalized precision immunotherapy program is on track to begin a Phase 1 study in the second half of 2026.
Source:
https://www.curevac.com/en/curevac-announces-financial-results-for-the-fourth-quarter-and-full-year-2024-and-provides-business-update/
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
